COMPLIANCE INFO_2019 - Laserfiche WebLink

Home Browse Search

Zip and Tray Developer SDS page 3 of 4 rev. May 1, 7n',: Engineering Controls Control airborne concentrations below the exposure limits. Use only with adequate ventilation. Local exhaust ventilation may be necessary. Respiratory When respiratory protection is required, use a NIOSH approved air-purifying respirator Protection equipped with a combination high efficiency filter and organic vapors canister. For emergency and other conditions where exposure limits may be greatly exceeded,use an approved positive-pressure,self-contained breathing apparatus or positive-pressure air line with auxiliary self-contained air supply. Skin Protection For brief contact,no precautions other than clean body-covering clothing should be needed. Use chemical resistant gloves,such as nitrile or polychloroprene. Eye Protection I Use safety lasses with side shields or,preferably,chemical goggles. 9. Physical and Chemical Properties Boiling Point >100°C Specific Gravity 1.15-1.20 %Volatiles 78% water Solubility in Water Soluble in all proportions pH 11.3-11.7 Odor Odorless Form Liquid Color Pale amber VOC 60 /L 10. Stability and Reactivity Chemical Stability Stable under normal storage conditions Conditions to Avoid Do not mix with strong acids Incompatibility Strong acids Hazardous None Decomposition Products Hazardous Will not occur Polymerization 11. Toxicological Information Results of component to icity testperformed: Data for Sodium Acute Toxicity Data:Oral LD50:>500 mg/kg(rabbit).Dermal LD50:>2 g/kg(rabbit). Inhalation hydroxide LC50:>40 mg/cubic meter/1 hour(rat).Skin irritation:Causes burns to eyes and skin. (CAS 1310-73-2) Data for Sodium Acute Toxicity Data:Oral(Rat)LD50:>1600 mg/Kg.Skin irritation:none. Eye irritation:slight; sulphite washing palliative.Can cause allergic reactions(headaches,difficulty in breathing,rapid heart (CAS 7757-83-7) rate and anaphylaxis)to susceptible individuals. Data for hydroquinone Acute Toxicity Data: Oral LD50(rat):400 mg/kg. Oral LD50(male rat):400 mg/kg.Oral LD50 (CAS 123-31-9) (male mouse): 100-200 mg/kg. Dermal LD50(guinea pig):>1,000 mg/kg. Dermal absorption rate: 1.1 micrograms(s)/cm 2/hour.Skin irritation:slight. Skin Sensitization:positive. Eye irritation:moderate. Mutagenicity/Genotoxicity Data: Salmonella typhimurium assay(Ames test):negative(in presence and absence of Chromosomal aberration assay:negative(in absence of activation)Chromosomal aberration assay:positive(in presence of activation) Sister chromatid exchange(SCE)assay:positive(in presence and absence of activation) Definitions for the following section(s): LOEL=lowest-observed-effect level, LOAEL=lowest observed-adverse-effect, NOAEL=no observed-adverse-effect level, NOEL=no-observed- effect level.Repeated dose toxicity: Dermal(17-day,rat):NOEL;3800 mg/kg/day. Dermal (17-day):LOEL(Lowest observable effect level);4800 mg/kg/day. Developmental Toxicity Data: Oral(female rabbit):NOEL for developmental toxicity;25mg/kg/day. There is insufficient evidence for classifying hydroquinone as a suspected carcinogenic or mutagenic substance in humans.No increases in cancer rates were observed in an epidemiology study which looked at mortality among more than 800 persons employed primarily in the manufacture of hydroquinone.Carcinogenicity studies in animals were inconclusive.Rats and mice were given hydroquinone by stomach tube or at high concentrations in the diet.Responses were not consistent across route of exposure,species or sex.The International Agency for Research on Cancer(IARC)has classified hydroquinone in Group 3,i.e.,"not classifiable"as a carcinogen. Hydroquinone is generally negative in bacterial mutagenicity tests;there is evidence for the clastogenicity(chromosome breakage)of hydroquinone in vivo and in vitro.The relevance of chromosomal effects in test animals in predicting human risk is unclear. Human experience:See listed components above. This product does not contain any compounds listed by NTP or IARC or regulated by OSHA as a carcinogen.